Toggle Nav
Close
  • Menu
  • Setting

Tyrosine Kinase

Tyrosine kinase is a large group of proteins regulates the function of cell growth, differentiation, motility, cytoskeletal rearrangement and adhesion etc. They activate the target protein through transfer of phosphate from ATP to the hydroxyl group of a target protein tyrosine. Transmembrane receptor kinases and non-receptor cytoplasmic kinases are two main categories of the tyrosine kinases.

Receptor tyrosine kinases bind to extracellular ligands/growth factors, which promotes receptor dimerization and autophosphorylation of receptor tyrosine residues. This triggers a cascade of downstream events through phosphorylation of intracellular proteins that ultimately transduce the extracellular signal to the nucleus, causing changes in gene expression. Receptor tyrosine kinases include EGFR/ErbB, PDGFR, VEGFR, FGFR and MET subfamilies etc. Dysfunctions in tyrosine phosphorylation are linked to oncogenic transformation. In additions, various adaptor and effector proteins couple to carboxy-terminal of an active kinase. For instance, binding of the GRB2 adaptor protein activates EGFR and MAPK/ERK signaling.

Non-receptor tyrosine kinases involve many well-defined proteins (e.g. the Src family kinases, c-Abl, and Jak kinases) and other kinases which regulates cell growth and differentiation. For example, Src family kinases are curial for activating and inhibitory pathways in the innate immune response.

Items 1-10 of 19

Page
per page
  1. Pazopanib (GW-786034)
    A3022 Pazopanib (GW-786034)
    Target: CSF-1R|VEGFR|PDGFR|c-Kit|FGFR
    Summary: VEGFR/PDGFR/FGFR inhibitor
      insoluble in EtOH; insoluble in H2O; ≥10.95 mg/mL
  2. Dovitinib (TKI258) Lactate
    B5953 Dovitinib (TKI258) Lactate
    Target: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFR
    Summary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).
      insoluble in EtOH; ≥10.62 mg/mL
  3. Regorafenib hydrochloride
    A3750 Regorafenib hydrochloride
    Target: Raf|VEGFR|PDGFR|c-Kit|c-RET
    Summary: Tyrosine kinase inhibitor
      ≥25.95 mg/mL
  4. SU 5402
    A3843 SU 5402
    Target: VEGFR|PDGFR|FGFR
    Summary: VEGFR2/FGFR/PDGFR/EGFR inhibitor
      insoluble in EtOH; insoluble in H2O; ≥14.8 mg/mL
  5. Imatinib (STI571)
    B2171 Imatinib (STI571)
    Target: PDGFR|c-Kit|Bcr-Abl
    Summary: Protein-tyrosine kinase inhibitor
      ≥24.68 mg/mL
  6. Regorafenib
    A8236 Regorafenib
     4 Citation
    Target: Raf|VEGFR|PDGFR|c-Kit|RET
    Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1
      ≥25.04 mg/mL
  7. Nintedanib (BIBF 1120)
    A8252 Nintedanib (BIBF 1120)
     3 Citation
    Target: VEGFR|PDGFR|FGFR
    Summary: VEGFR/PDGFR/FGFR inhibitor
      insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
  8. Masitinib (AB1010)
    A2942 Masitinib (AB1010)
    Target: PDGFR|c-Kit|Lyn
    Summary: Tyrosine kinase inhibitor, potent and selective
      ≥24.95 mg/mL
  9. Linifanib (ABT-869)
    A2949 Linifanib (ABT-869)
    Target: VEGFR|PDGFR
    Summary: VEGFR/PDGFR inhibitor
      insoluble in H2O; insoluble in EtOH; ≥18.75 mg/mL
  10. Dovitinib (TKI-258, CHIR-258)
    A2168 Dovitinib (TKI-258, CHIR-258)
     2 Citation
    Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR
    Summary: Multitargeted RTK inhibitor
      insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL

Items 1-10 of 19

Page
per page